ELISA News and Research

RSS

Study: Graphene nanoparticles interfere with the development of anxiety-related behaviors in vertebrates

New research shows that the nanomaterial acts on the excitatory synapses, interfering with the development of anxiety related behaviors in vertebrates.

11 Mar 2021

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

A new study adds to the sum of knowledge around this issue, showing a highly synchronized and rapid development of an antibody response in breast milk and serum, which reached stable levels around two weeks after the second dose of the vaccine was administered.

10 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Researchers have developed small proteins from sequences in SARS-CoV-2's RBD that bind to ACE2. These were as effective in binding to neutralizing antibodies as larger RBD proteins.

2 Mar 2021

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for detecting anti-SARS-CoV-2 neutralizing antibodies in serum samples. According to the scientists, the test can be effectively used for population-level serosurveillance and evaluation of vaccine efficacy. The study is currently available on the medRxiv* preprint server.

1 Mar 2021

Researchers investigate the duration of the immune response to SARS-CoV-2

The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new Penn State-led study.

26 Feb 2021

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Austria was observed in the Ski resort Ischgl in early March 2020. Later, the virus spread across Austria and other countries in Northern Europe.

25 Feb 2021

Novel single-particle digital assay using plasmonic nanobubbles

An interdisciplinary team from the University of Texas applied DIAMOND to the respiratory syncytial virus (RSV) diagnostics and demonstrated that DIAMOND is 150 times more sensitive than commercial lateral flow assays. They found that the measurements are completed within 2 minutes. The results of this study are published on the medRxiv* preprint server.

25 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers have measured the galectin-3 levels in the sera of hospitalized patients. They found initial high levels indicate patients will become severely ill, suggesting it could be used as a predictor of severe disease.

10 Feb 2021

Researchers create bone replicas using a hot nano-chisel

A holy grail for orthopedic research is a method for not only creating artificial bone tissue that precisely matches the real thing, but does so in such microscopic detail that it includes tiny structures potentially important for stem cell differentiation, which is key to bone regeneration.

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

ELISA News and Research

Study: Graphene nanoparticles interfere with the development of anxiety-related behaviors in vertebrates

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Could small synthetic antigen proteins be diagnostic tools for SARS-CoV-2?

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

Researchers investigate the duration of the immune response to SARS-CoV-2

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Novel single-particle digital assay using plasmonic nanobubbles

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

SARS-CoV-2 DNA vaccine tested in animal model

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

SARS-CoV-2 D614G mutation associated with lower antibody binding

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers create bone replicas using a hot nano-chisel

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Insight into role of aging in response to SARS-CoV-2 infection

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News